Otitis Media - Pipeline Review, H2 2016

PUNE, INDIA, August 30, 2016 /EINPresswire.com/ -- Summary

‘Otitis Media - Pipeline Review, H2 2016’, provides an overview of the Otitis Media pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619242-otitis-media-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619242-otitis-media-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Otitis Media
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619242-otitis-media-pipeline-review-h2-2016

Key points in table of content
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Otitis Media Overview 8
Therapeutics Development 9
Pipeline Products for Otitis Media - Overview 9
Pipeline Products for Otitis Media - Comparative Analysis 10
Otitis Media - Therapeutics under Development by Companies 11
Otitis Media - Therapeutics under Investigation by Universities/Institutes 12
Otitis Media - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Otitis Media - Products under Development by Companies 16
Otitis Media - Products under Investigation by Universities/Institutes 17
Otitis Media - Companies Involved in Therapeutics Development 18
Cellceutix Corporation 18
ContraFect Corporation 19
GlaxoSmithKline Plc 20
Lee's Pharmaceutical Holdings Limited 21
Madam Therapeutics B.V. 22
Merck & Co., Inc. 23
MerLion Pharmaceuticals Pte Ltd 24
Oticpharma Ltd 25
Otonomy, Inc. 26
Yuhan Corporation 27
Otitis Media - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
betahistine dihydrochloride - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
brilacidin tetrahydrochloride - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CF-303 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CF-309 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ciprofloxacin hydrochloride - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ciprofloxacin hydrochloride SR - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
finafloxacin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GSK-2189242A - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
pazufloxacin - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
PCL-1402 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules for Otitis Media - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619242

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.